Muhammet Tanc
CEO Nuclide Therapeutics
Muhammet Tanc, PhD, is Co-Founder & CEO of Nuclide Therapeutics, a biotech company developing next-generation radiotheranostics for therapy-resistant cancers. With over 15 years of experience in cancer drug development across academia and translational research, he works at the intersection of drug discovery, radiopharmaceutical innovation, and clinical translation. He is focused on building science-driven programmes into clinically impactful, investable companies.
Seminars
Wednesday 2nd December 2026
Beyond Regulatory Requirements: Maximising the Value of Toxicology Studies to De-Risk Preclinical Development
2:00 pm
- Understanding the critical role of toxicology studies in supporting safe and successful radiopharmaceutical development
- Exploring how developers can generate additional translational insights from toxicology programmes beyond minimum regulatory requirements
- Examining the unique considerations associated with designing and interpreting toxicology studies for radiopharmaceuticals
Thursday 3rd December 2026
Targeting Therapy-Resistant Cancer with Radiotheranostics: Preclinical Insights from ALDH1A1- Directed Development
11:00 am
- Presenting preclinical data supporting the development of ALDH1A1-targeted radiotheranostics in therapy-resistant cancers
- Exploring the rationale for targeting resistance-associated biology and assessing its potential to address unmet clinical need
- Evaluating the translational challenges associated with advancing novel intracellular targets toward clinical development
